German Biotech Gets €47M To Treat Painful Inflammatory Disease

InflaRx has raised $55M (€47M) in a Series D fundraising in order to get its lead anti-inflammatory drug, IFX-1, through late-stage development. 

A year after its €31M Series C, InflaRx is closing a Series D round. The company has raised a total of $55M (€47M) from a team of US investors co-led by Bain Capital Life Sciences, Cormorant Asset Management and RA Capital Management. Of the total sum, $25M (€21M) was raised in the form of a share purchase.

The fresh cash will be invested in advancing IFX-1, the company’s lead drug candidate through Phase IIb as well as advance its preclinical pipeline. IFX-1 is an antibody that blocks human complement factor C5a, a fragment of a protein called C5 that acts as an amplifier of the inflammatory response. Unlike other drugs that completely block the C5 protein by cleaving it, IFX-1 only targets the C5a fragment, leaving intact another fragment called C5b-9, which plays an important role in protecting the body from infections.

IFX-1 successfully completed a Phase IIa in July in patients with hidradenitis suppurativa, a chronic auto-inflammatory disease that causes the development of big, painful pimp-like bumps in the skin that leave big scars behind. With such a big Series D fundraising, the company is now ready to take on a Phase II study on the same condition.

Image via Lightspring /Shutterstock

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.